Adiponectin and Its Role in Weight Loss and Disease Prevention

Adiponectin (abbreviated ADPN) is a peptide hormone synthesized and secreted by adipocytes—fat tissue cells—comprising a polypeptide chain of 244 amino acid residues. Its structural architecture features two distinct domains: a globular domain (responsible for biological activity) and a collagen-like domain (facilitating multimerization processes). Upon secretion into circulation, it undergoes aggregation into three primary fractions with varying molecular weights: low-molecular-weight (LMW), medium-molecular-weight (MMW), and high-molecular-weight (HMW) adiponectin, each fulfilling discrete regulatory roles within the organism. Although adiponectin constitutes merely 0.01% of the total plasma protein pool, its concentration—ranging from 1 to 30 µg/ml on average—ranks among the highest of peptide hormones. Its prolonged half-life ensures relative stability of circulating levels. Pronounced gender disparities exist: women exhibit significantly higher ADPN concentrations than men. Adiponectin expression is modulated by a spectrum of metabolic and demographic factors, demonstrating an inverse correlation with body mass index (BMI), insulinemia, the homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride levels, and blood pressure, while positively correlating with high-density lipoprotein cholesterol (HDL-C) concentrations and age. Diminished adiponectin levels are observed in individuals with obesity, type 2 diabetes mellitus, hypertension, a history of stroke, and coronary artery disease—implicating its pivotal role in the pathogenesis of these conditions. Among its isoforms, the high-molecular-weight fraction (HMW) holds the greatest clinical significance, as reduced HMW levels—even in the context of elevated total ADPN—are associated with impaired multimerization and predispose to metabolic dysfunctions (including insulin resistance, atherosclerosis, and diabetes). Paradoxically, in autoimmune inflammatory diseases (e.g., rheumatoid arthritis), adiponectin may exert pro-inflammatory effects, underscoring the contextual complexity of its physiological functions. Thus, the beneficial metabolic actions are closely linked to the HMW fraction and primarily pertain to metabolic disorders, whereas total ADPN concentration does not fully reflect its biological activity.

Adiponectin has an important role in regulating glucose and lipid metabolism and is therefore one of the hormones responsible for maintaining proper body weight. The fibrous receptors for ADPN present in skeletal muscles stimulate the activity of enzymes that are responsible for increasing glucose uptake and oxidation and increasing fatty acid oxidation.

Adiponectin, an adipose tissue-derived protein with exclusive secretory origin, exerts multifaceted protective effects against metabolic and vascular disorders. Its high-molecular-weight isoform (HMW-adiponectin) mediates direct endothelial preservation by modulating inflammatory, oxidative, and thrombotic pathways. Through activation of endothelial nitric oxide synthase (eNOS) and the consequent elevation in nitric oxide (NO) bioavailability, adiponectin promotes vasodilation, reduces peripheral vascular resistance, and lowers blood pressure. Additionally, it suppresses reactive oxygen species generation, downregulates pro-inflammatory cytokine expression (e.g., TNF-α, IL-6), and attenuates LDL lipid peroxidation, thereby mitigating atherosclerotic plaque progression and thrombotic risk. Within glucose metabolism, adiponectin functions as an endogenous insulin sensitizer: it enhances glucose uptake in peripheral tissues (particularly skeletal muscle), inhibits hepatic gluconeogenesis, and optimizes fatty acid oxidation, collectively counteracting insulin resistance development. The *ACDC* gene, encoding this adipokine, undergoes selective expression in adipocytes, with mutations correlating to impaired protein multimerization and metabolic dysregulation susceptibility. Emerging evidence further links hypoadiponectinemia to elevated type 2 diabetes risk, positioning adiponectin augmentation or pharmacological modulation as a potential preventive and therapeutic avenue.

Scientific evidence demonstrates a significant inverse relationship between adiponectin (ADPN) concentrations and the degree of obesity, with obese individuals exhibiting markedly lower levels of this hormone compared to those with a normal body mass index [4]. This peptide plays a protective role against obesity-related dysfunctions through multiple mechanisms, including: attenuation of hyperglycemia, enhancement of insulin-mediated glucose uptake (thereby improving tissue insulin sensitivity), optimization of glucose metabolism, and reduction of elevated free fatty acids, triglycerides, and pro-inflammatory mediators such as C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) [5]. Collectively, these ADPN-driven processes facilitate effective fat mass reduction and correct metabolic disturbances commonly associated with overweight and obesity. Furthermore, adiponectin exhibits preventive potential against conditions such as type 2 diabetes mellitus, insulin resistance, atherosclerosis, and hypertension—pathologies closely linked to excessive adipose tissue accumulation. The high-molecular-weight (HMW) isoform of adiponectin demonstrates the most potent metabolic effects, including enhanced insulin sensitivity, accelerated fatty acid oxidation, and endothelial protection. However, in the context of autoimmune diseases characterized by chronic inflammation, the role of adiponectin appears less beneficial, highlighting the multifaceted nature of its biological functions. Given that the precise mechanisms of ADPN action remain incompletely understood, this area warrants further in-depth scientific exploration.